drugset
drugset / Trial / NCT02888236

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

NCT02888236 ↗

Phase 2 Completed 36 enrolled LEO Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study of LEO 32731 in the treatment of psoriasis vulgaris

Timeline

Start
2016-09
Primary completion
2017-06-20
Completion
2017-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 32731 Unknown 30 mg Oral

Indications

psoriasis